文献速递白血病

一线伊马替尼对比二代和三代酪氨酸激酶抑制剂治疗慢性期慢性髓性白血病:系统评价与荟萃分析

First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis.
PubMed 文献 · Blood Adv · 2020-01-01

该系统评价纳入1990至2019年发表的7项随机对照试验(3262例初诊费城染色体阳性慢性期慢性髓性白血病成人患者),比较一线伊马替尼与二代(达沙替尼、尼洛替尼、博舒替尼)及三代(普纳替尼)酪氨酸激酶抑制剂。二代和三代酪氨酸激酶抑制剂改善3个月主要分子学反应并减少加速/急变期转化,但血小板减少、心血管事件、胰腺和肝脏不良反应更多;伊马替尼在合并症患者中可能因更安全的毒性特征而成为更好选择。

要点

  • 二代和三代酪氨酸激酶抑制剂较伊马替尼改善3个月主要分子学反应(RR 4.28,95%CI 2.20-8.32)。
  • 二代和三代酪氨酸激酶抑制剂减少加速/急变期转化(RR 0.44,95%CI 0.26-0.74)。
  • 二代和三代酪氨酸激酶抑制剂增加血小板减少、心血管事件、胰腺和肝脏不良反应。

核心结论

  • 与伊马替尼相比,二代和三代酪氨酸激酶抑制剂改善临床反应,但伊马替尼更安全的毒性特征可能使其成为合并症患者的更好选择。

研究设计与样本

  • 系统评价与荟萃分析,纳入1990至2019年发表的7项随机对照试验,共3262例初诊费城染色体阳性慢性期慢性髓性白血病成人患者。
  • 证据质量采用推荐分级的评估、制定与评价(GRADE)方法评估,证据确定性范围为高至中等。

主要发现

  • 两项随机对照试验(伊马替尼对比尼洛替尼、伊马替尼对比达沙替尼)发现5年总生存或无进展生存无差异。
  • 二代和三代酪氨酸激酶抑制剂改善3个月主要分子学反应(RR 4.28,95%CI 2.20-8.32)及其他疗效结局。
  • 二代和三代酪氨酸激酶抑制剂减少加速/急变期转化(RR 0.44,95%CI 0.26-0.74)。
  • 二代和三代酪氨酸激酶抑制剂与更多血小板减少(RR 1.57,95%CI 1.20-2.05)、心血管事件(RR 2.54,95%CI 1.49-4.33)、胰腺效应(RR 2.29,95%CI 1.32-3.96)和肝脏效应(RR 3.51,95%CI 1.55-7.92)相关。

关键数值与推荐

  • 3个月主要分子学反应:二代和三代酪氨酸激酶抑制剂对比伊马替尼的RR为4.28(95%CI 2.20-8.32)。
  • 加速/急变期转化:二代和三代酪氨酸激酶抑制剂对比伊马替尼的RR为0.44(95%CI 0.26-0.74)。
  • 血小板减少:二代和三代酪氨酸激酶抑制剂对比伊马替尼的RR为1.57(95%CI 1.20-2.05)。
  • 心血管事件:二代和三代酪氨酸激酶抑制剂对比伊马替尼的RR为2.54(95%CI 1.49-4.33)。
  • 胰腺效应:二代和三代酪氨酸激酶抑制剂对比伊马替尼的RR为2.29(95%CI 1.32-3.96);肝脏效应:RR为3.51(95%CI 1.55-7.92)。

临床怎么用

  • 作者认为,伊马替尼更安全的毒性特征可能使其成为合并症患者的更好选择。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Imatinib, the first tyrosine kinase inhibitor (TKI) for the treatment of chronic myeloid leukemia (CML), improves overall survival (OS), but the introduction of newer TKIs requires the definition of the optimal first-line TKI for newly diagnosed Philadelphia chromosome-positive (Ph+) chronic-phase (CP) CML. This systematic review of randomized controlled trials (RCTs) compares the efficacy and safety of imatinib vs second-generation (dasatinib, nilotinib, bosutinib) and third-generation TKIs (ponatinib) in adults with newly diagnosed Ph+ CP CML, concentrating on OS, progression-free survival (PFS), and hematological and nonhematological adverse events. The quality of the evidence was assessed using the Grading of Recommendations, Assessment, Development and Evaluation (GRADE) method. Seven RCTs published between 1990 and 2019 (involving 3262 participants) satisfied the eligibility criteria. Two RCTs (imatinib vs nilotinib and imatinib vs dasatinib) found no difference in 5-year OS or PFS. Second- and third-generation TKIs improved 3-month major molecular responses (relative risk [RR], 4.28; 95% confidence interval [CI], 2.20-8.32) and other efficacy outcomes, decreased accelerated/blastic-phase transformations (RR, 0.44; 95% CI, 0.26-0.74), but were associated with more cases of thrombocytopenia (RR, 1.57; 95% CI, 1.20-2.05), cardiovascular events (RR, 2.54; 95% CI, 1.49-4.33), and pancreatic (RR, 2.29; 95% CI, 1.32-3.96) and hepatic effects (RR, 3.51; 95% CI 1.55-7.92). GRADE showed that the certainty of the evidence ranged from high to moderate. This study shows that, in comparison with imatinib, second- and third-generation TKIs improve clinical responses, but the safer toxicity profile of imatinib may make it a better option for patients with comorbidities.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Vener C, Banzi R, Ambrogi F, et al. First-line imatinib vs second- and third-generation TKIs for chronic-phase CML: a systematic review and meta-analysis. Blood Adv. 2020. PMID: 32559295. doi:10.1182/bloodadvances.2019001329

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。